Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 54

Sort by

Sort Order Select

Journal Articles

Rapid Infusion Daratumumab Is Safe in Patients with AL Amyloidosis

Nathaniel Rosko, PharmD, Hanjie Mo, PharmD, Joslyn Rudoni, PharmD, Caitlin Siebenaller, PharmD, Sarah S Lee, MD, Rajshekar Chakraborty, MD, Beth M. Faiman, PhDCNP, Jack Khouri, MD, Alex V. Mejia Garcia, MD, Christy J. Samaras, DO, Faiz Anwer, MD, Jason Valent, MD

Blood (2019) 134 (Supplement_1): 1838.

https://doi.org/10.1182/blood-2019-124775

Published: 2019

Journal Articles

Efficacy and Safety of Low Molecular Weight Iron Dextran (LMWID) Vs. Ferumoxytol in Treating Iron Deficiency Anemia

Arpine Khudanyan, BS, Sven Reid Olson, MD, Thomas G. Deloughery, MD, Joseph J Shatzel, MD

Blood (2019) 134 (Supplement_1): 2449.

https://doi.org/10.1182/blood-2019-129653

Published: 2019

Journal Articles

Prevention and Management of Daratumumab Mediated Infusion Related Hypersensitivity Reactions Pre-and Post-Implementation of Rapid Infusion Protocol

My L Nguyen, PharmD, Catherine Burdalski, PharmD, BCOP, Syed Abbas Ali, MD, Lindsay Kohler, BS, PharmD Candidate, Steven Gilmore, PharmD, BCOP

Blood (2019) 134 (Supplement_1): 5811.

https://doi.org/10.1182/blood-2019-125391

Published: 2019

Journal Articles

Single Arm, Prospective, Open-Label Phase II Trial to Evaluate the Efficacy of Isatuximab in Patients with Monoclonal Gammopathy of Renal Significance

Vikram Premkumar, MD, Suzanne Lentzsch, MD PhD, Divaya Bhutani, MD

Blood (2019) 134 (Supplement_1): 3161.

https://doi.org/10.1182/blood-2019-123496

Published: 2019

Journal Articles

Evaluation of Infusion Reactions in Patients Receiving Daratumumab Post-Implementation of an Augmented Pre- and Peri-Medication Regimen

Patrick McBride, PharmD, Houry Leblebjian, PharmD, Paul Richardson, Jacob Laubach, MD, Hillary Prescott, PharmD

Blood (2018) 132 (Supplement 1): 3234.

https://doi.org/10.1182/blood-2018-99-111361

Published: 2018

Journal Articles

Evaluation of Intravenous Diphenhydramine Use in Patients with Sickle Cell Vaso-Occlusive Crisis

Ifeyinwa Osunkwo, MD MPH, Shelby Merchant, PharmD, Rachel Crawford, PharmD, BCPS, Katherine Rector, PharmD, BCPS, Justin Arnall, PharmD, CPP, BCOP, James T Symanowski, PhD, Padmaja Veeramreddy, MD

Blood (2018) 132 (Supplement 1): 3575.

https://doi.org/10.1182/blood-2018-99-116848

Published: 2018

Journal Articles

Safety, Tolerability and Response Rates of Daratumumab in Patients with Relapsed Light Chain (AL) Amyloidosis: Results of a Phase II Study

Vaishali Sanchorawala, MD, Shayna Sarosiek, MD, John Mark Sloan, MD, Dina Brauneis, NP, Mary Ellen Migre, Meredith Mistark, Stephanie Santos, Ramon Cruz, Salli Fennessey, Anthony C Shelton, RN

Blood (2018) 132 (Supplement 1): 2005.

https://doi.org/10.1182/blood-2018-99-112991

Published: 2018

Journal Articles

Safety and Tolerability of Daratumumab in Patients with Relapsed Light Chain (AL) Amyloidosis: Preliminary Results of a Phase II Study

Vaishali Sanchorawala, MD, Shayna Sarosiek, MD, John Mark Sloan, MD, Dina Brauneis, NP, Mary Ellen Migre, Meredith Mistark, Stephanie Santos, Salli Fennessey, Anthony C Shelton, RN

Blood (2017) 130 (Supplement 1): 507.

https://doi.org/10.1182/blood.V130.Suppl_1.507.507

Published: 2017

Journal Articles

Drug-Induced Immune Thrombocytopenia (DITP) Caused By Multiple Drug-Dependent Platelet-Reactive Antibodies (DDAbs) in Patients Undergoing Oxaliplatin-Containing Combination Chemotherapy for Metastatic Colon Cancer

Brian R. Curtis, PhDMT(ASCP), Yen-Michael S. Hsu, MD PhD, Nikolai A. Podoltsev, MD PhD, Jill Lacy, MD, Susanna A Curtis, MD, Robert Andrew Desimone, MD, Michael Samuel, MD, Kristin Zutavern, BS, Daniel Bougie, PhD, Richard H. Aster, MD

Blood (2017) 130 (Supplement 1): 3625.

https://doi.org/10.1182/blood.V130.Suppl_1.3625.3625

Published: 2017

Journal Articles

Interpretation of TEG Studies in Management of a Severe Glanzmann Thrombasthenia Patient

Paulette Bryant, MD, Katie Andricopulos, PharmD, BCPPS

Blood (2017) 130 (Supplement 1): 4854.

https://doi.org/10.1182/blood.V130.Suppl_1.4854.4854

Published: 2017

Journal Articles

Monoclonal Antibody Utilization Characteritics in Patients with Multiple Myeloma

Sikander Ailawadhi, Abdel-Ghani Azzouqa, Zahara Meghji, Tania Jain, MD, Nancy Diehl, Stephanie P. Gebhardt, Vishal Shah, David O. Hodge, MS, Raj Patel, MD, Prachi Jani, MD, Taimur Sher, MD, Vivek Roy, MD, Meghna Ailawadhi, MD, Victoria R. Alegria, Aneel Paulus, MD, Asher A. Chanan-Khan, MD, Rafael Fonseca, MD

Blood (2017) 130 (Supplement 1): 5440.

https://doi.org/10.1182/blood.V130.Suppl_1.5440.5440

Published: 2017

Journal Articles

Extended Duration of Anti-Thymocyte Globulin (ATG) Administration May Reduce the Risk of Graft-Versus-Host Disease in Patients with Aplastic Anemia Undergoing Matched-Related Allogeneic Peripheral Blood Stem Cell Transplantation

Laura A. Zider, MSN, ACNP-BC, RN, Amanda N. Seddon, PharmD, Sunita Nathan, MD, John J. Maciejewski, MD PhD, Jamile M. Shammo, MD, Gorgun Akpek, MD MHS

Blood (2016) 128 (22): 5876.

https://doi.org/10.1182/blood.V128.22.5876.5876

Published: 2016

Journal Articles

Phase Ib Study of Isatuximab and Carfilzomib in Relapse and Refractory Multiple Myeloma

Thomas G. Martin, III, MD, Gabriel N Mannis, Ajai Chari, MD, Pamela Munster, MD, Frank Campana, MD, Ai-Min Hui, MD PhD, Jeffrey L. Wolf, MD

Blood (2016) 128 (22): 2111.

https://doi.org/10.1182/blood.V128.22.2111.2111

Published: 2016

Journal Articles

Autologous Cord Blood Infusion for the Treatment of Brain Injury in Children with Cerebral Palsy

Jessica Sun, MD, Mohamad Mikati, MD, Jesse Troy, PhD, Kathryn Gustafson, PhD, Ryan Simmons, MS, Ricki Goldstein, MD, Jodi Petry, MS, OTR/L, Colleen McLaughlin, DNP, Barbara Waters-Pick, BS, MT(ASCP), Laura Case, PT, DPT, Gordon Worley, MD, Joanne Kurtzberg, MD

Blood (2015) 126 (23): 925.

https://doi.org/10.1182/blood.V126.23.925.925

Published: 2015

Journal Articles

Management of Infusion-Related Reactions Following Daratumumab Monotherapy in Patients with at Least 3 Lines of Prior Therapy or Double Refractory Multiple Myeloma (MM): 54767414MMY2002 (Sirius)

Peter M. Voorhees, Brendan Weiss, Saad Usmani, Huaibao Feng, Clarissa Uhlar, Imran Khan, Tahamtan Ahmadi, Sagar Lonial, MD

Blood (2015) 126 (23): 1829.

https://doi.org/10.1182/blood.V126.23.1829.1829

Published: 2015

Journal Articles

Front-Line Treatment with Ofatumumab for Older Unfit Patients with Chronic Lymphocytic Leukemia

Candida Vitale, MD, Maria Ciccone, MD, Christina Hinojosa, Michael Keating, MBBS, Naveen Pemmaraju, MD, Susan O'Brien, MD, William Wierda, MD PhD, Deborah A Thomas, MD, Gautam Borthakur, MD, Maro Ohanian, DO, Jan A. Burger, MD PhD, Alessandra Ferrajoli, MD

Blood (2015) 126 (23): 5292.

https://doi.org/10.1182/blood.V126.23.5292.5292

Published: 2015

Journal Articles

'First-in-human' phase I dose escalation trial of IL-15N72D/IL-15Rα-Fc superagonist complex (ALT-803) demonstrates immune activation with anti-tumor activity in patients with relapsed hematological malignancy

Jeffrey S. Miller, MD, Sarah Cooley, MD, Shernan Holtan, Mukta Arora, MD, Celalettin Ustun, MD, Emily Jeng, Hing C. Wong, Michael R. Verneris, MD, John E. Wagner, MD, Daniel J. Weisdorf, MD, Bruce R. Blazar, MD, Todd A Fehniger, MD PhD, Rizwan Romee, MD

Blood (2015) 126 (23): 1957.

https://doi.org/10.1182/blood.V126.23.1957.1957

Published: 2015

Journal Articles

Utility of Continuous Diphenhydramine Infusion in Severe Mast Cell Activation Syndrome

Lawrence B Afrin, MD

Blood (2015) 126 (23): 5194.

https://doi.org/10.1182/blood.V126.23.5194.5194

Published: 2015

Journal Articles

Efficacy and Safety of Intravenous Ferric Carboxymaltose in Children with Iron Deficiency Anemia Unresponsive to Oral Iron Therapy

Jacquelyn M. Powers, MD, Mark P. Shamoun, MD, Timothy L. McCavit, MD, Leah Adix, CCRP, George R. Buchanan, MD

Blood (2015) 126 (23): 4552.

https://doi.org/10.1182/blood.V126.23.4552.4552

Published: 2015

Journal Articles

A Phase II Trial Evaluating the Safety of Rapid Infusion Ofatumumab (OFA) in Patients (pts) with Previously Treated Chronic Lymphocytic Leukemia (CLL)

William B. Donnellan, MD, Jesus Berdeja, MD, Dianna Shipley, MD, Edward Arrowsmith, MD MPH, David Wright, MD, Scott Lunin, MD, Richard H. Brown, MD, James Essell, MD, Ian Flinn

Blood (2014) 124 (21): 3336.

https://doi.org/10.1182/blood.V124.21.3336.3336

Published: 2014

NARROW

Rapid Infusion Daratumumab Is Safe in Patients with AL Amyloidosis

Efficacy and Safety of Low Molecular Weight Iron Dextran (LMWID) Vs. Ferumoxytol in Treating Iron Deficiency Anemia

Prevention and Management of Daratumumab Mediated Infusion Related Hypersensitivity Reactions Pre-and Post-Implementation of Rapid Infusion Protocol

Single Arm, Prospective, Open-Label Phase II Trial to Evaluate the Efficacy of Isatuximab in Patients with Monoclonal Gammopathy of Renal Significance

Evaluation of Infusion Reactions in Patients Receiving Daratumumab Post-Implementation of an Augmented Pre- and Peri-Medication Regimen

Evaluation of Intravenous Diphenhydramine Use in Patients with Sickle Cell Vaso-Occlusive Crisis

Safety, Tolerability and Response Rates of Daratumumab in Patients with Relapsed Light Chain (AL) Amyloidosis: Results of a Phase II Study

Safety and Tolerability of Daratumumab in Patients with Relapsed Light Chain (AL) Amyloidosis: Preliminary Results of a Phase II Study

Drug-Induced Immune Thrombocytopenia (DITP) Caused By Multiple Drug-Dependent Platelet-Reactive Antibodies (DDAbs) in Patients Undergoing Oxaliplatin-Containing Combination Chemotherapy for Metastatic Colon Cancer

Interpretation of TEG Studies in Management of a Severe Glanzmann Thrombasthenia Patient

Monoclonal Antibody Utilization Characteritics in Patients with Multiple Myeloma

Extended Duration of Anti-Thymocyte Globulin (ATG) Administration May Reduce the Risk of Graft-Versus-Host Disease in Patients with Aplastic Anemia Undergoing Matched-Related Allogeneic Peripheral Blood Stem Cell Transplantation

Phase Ib Study of Isatuximab and Carfilzomib in Relapse and Refractory Multiple Myeloma

Autologous Cord Blood Infusion for the Treatment of Brain Injury in Children with Cerebral Palsy

Management of Infusion-Related Reactions Following Daratumumab Monotherapy in Patients with at Least 3 Lines of Prior Therapy or Double Refractory Multiple Myeloma (MM): 54767414MMY2002 (Sirius)

Front-Line Treatment with Ofatumumab for Older Unfit Patients with Chronic Lymphocytic Leukemia

'First-in-human' phase I dose escalation trial of IL-15N72D/IL-15Rα-Fc superagonist complex (ALT-803) demonstrates immune activation with anti-tumor activity in patients with relapsed hematological malignancy

Utility of Continuous Diphenhydramine Infusion in Severe Mast Cell Activation Syndrome

Efficacy and Safety of Intravenous Ferric Carboxymaltose in Children with Iron Deficiency Anemia Unresponsive to Oral Iron Therapy

A Phase II Trial Evaluating the Safety of Rapid Infusion Ofatumumab (OFA) in Patients (pts) with Previously Treated Chronic Lymphocytic Leukemia (CLL)

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only